Hyperthyroidism does not directly cause cancer, but it is associated with a higher-than-expected rate of thyroid cancer and a modest increase in risk for certain other cancers, particularly breast cancer. The relationship is complex: the same immune processes and hormonal changes that drive an overactive thyroid can also create conditions that favor tumor growth.
Thyroid Cancer Risk in Hyperthyroid Patients
The strongest association between hyperthyroidism and cancer involves the thyroid gland itself. When patients with Graves’ disease (the most common autoimmune cause of hyperthyroidism) undergo thyroid surgery, about 7% are found to have thyroid cancer that wasn’t detected beforehand, with some studies reporting rates as high as 32%. The most common type found is papillary thyroid cancer, and in some patient populations the frequency has been reported at 34% or higher.
Toxic multinodular goiter, another common cause of hyperthyroidism, also carries a notable cancer risk. One study found malignancy in 21% of patients with this condition. This was significantly higher than in patients with a single overactive nodule, where the rate was about 4.5%.
There’s an important nuance here. Overactive (“hot”) thyroid nodules themselves rarely turn out to be cancerous. American Thyroid Association guidelines state that hyperfunctioning nodules rarely harbor malignancy, and biopsy of these nodules isn’t typically recommended. The greater danger comes from non-functioning (“cold”) nodules that may be hiding alongside the hot ones, or from cancer developing elsewhere in the gland. So the risk isn’t necessarily from the overactive nodule itself but from the thyroid environment as a whole.
Why Hyperthyroidism May Promote Cancer Growth
In Graves’ disease, the immune system produces antibodies that latch onto the same receptor that thyroid-stimulating hormone (TSH) uses. Some of these antibodies, called stimulating antibodies, don’t just trigger excess hormone production. They also switch on cellular pathways that promote cell division and suppress the natural self-destruction process that normally eliminates damaged cells. In effect, these antibodies can push thyroid cells to multiply while shielding them from the built-in safety mechanism that would otherwise clear abnormal cells.
Beyond immune-driven growth signals, excess thyroid hormone itself appears to play a role. Thyroid hormones regulate metabolism throughout the body and influence how quickly cells divide in many tissues. A large body of evidence suggests that both clinical and subclinical hyperthyroidism (where hormone levels are only mildly elevated) increase the risk of several solid tumors, while hypothyroidism may have the opposite effect, potentially slowing or delaying cancer development.
Breast Cancer and Other Non-Thyroid Risks
The link between hyperthyroidism and breast cancer has received growing attention. A large national cohort study found that women with hyperthyroidism had a 23% increased risk of developing breast cancer compared to the general population. The association was strongest for women with toxic nodular goiter, who faced a 38% increased risk. Women diagnosed with hyperthyroidism before age 40 had a particularly elevated breast cancer risk.
Several factors appear to contribute. Women with hyperthyroidism, especially toxic nodular goiter, tend to have denser breast tissue on mammograms, which is an independent risk factor for breast cancer. They also showed higher genetic risk scores for breast cancer. Hyperthyroidism was additionally linked to higher body mass index, earlier age at first birth, and shorter breastfeeding duration, all of which independently raise breast cancer risk. It’s not entirely clear whether excess thyroid hormone directly drives breast cancer or whether the two conditions share overlapping biological and genetic pathways.
Thyroid Cancer Tends to Be More Aggressive
When thyroid cancer does develop in someone with hyperthyroidism, it tends to behave more aggressively than thyroid cancer found in people with normal thyroid function. A study of over 2,800 thyroidectomies found that hyperthyroid patients with thyroid cancer had double the rate of lymph node spread (12.6% versus 6.1%) compared to patients with normal thyroid function. The five-year disease-free survival rate was also significantly lower: 89.1% versus 96.6%. Local recurrence rates trended higher as well, though that difference didn’t reach statistical significance.
These findings matter because thyroid cancer is often portrayed as a very treatable, slow-growing cancer. While that’s true for most cases, the subset of thyroid cancers arising in hyperthyroid patients appears to follow a more concerning course.
Radioactive Iodine Treatment and Secondary Cancers
It’s worth separating the cancer risk from hyperthyroidism itself from the risk introduced by one of its treatments. Radioactive iodine (RAI), commonly used to treat both hyperthyroidism and thyroid cancer, has its own cancer implications. Research from the National Cancer Institute found that RAI therapy for thyroid cancer in patients under 45 was associated with a 23% increased risk of developing a new solid cancer and a 92% increased risk of leukemia, compared to patients who didn’t receive RAI.
The leukemia risk rises within the first two to three years after treatment, while solid cancer risk climbs over the longer term, particularly 20 or more years after exposure. Specific solid cancers linked to RAI include salivary gland cancer (200% increased risk), uterine cancer (55%), lung cancer (42%), and breast cancer (18%). Those treated before age 25 face the highest long-term risk, which is why clinicians increasingly weigh the benefits of RAI carefully in younger patients.
What This Means for Screening
If you have hyperthyroidism, current guidelines recommend that any thyroid nodule larger than 1 centimeter should prompt a TSH blood test. If TSH is low (confirming hyperthyroidism), a radioactive scan helps determine whether a nodule is hot or cold. Hot nodules generally don’t need a biopsy. Cold or non-functioning nodules found during that workup do warrant further evaluation, typically with fine-needle aspiration, based on their size and appearance on ultrasound. Nodules with suspicious features on ultrasound are biopsied at 1 centimeter or larger, while those with a low-suspicion appearance may not need biopsy until they reach 1.5 to 2 centimeters.
The broader takeaway is that hyperthyroidism isn’t a direct carcinogen in the way that smoking or radiation exposure is. But the hormonal and immune disruptions it creates form an environment where cancer, particularly thyroid cancer, is more likely to develop and may behave more aggressively when it does. Thorough imaging and careful monitoring of nodules remain the most practical tools for catching any problems early.